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Background: Anticholinergic medication use is linked with increased cognitive decline, dementia, falls and
mortality, and their use should be limited in older people. Here we estimate the prevalence of anticholinergic use
in England’s older population in 1991 and 2011, and describe changes in use by participant’s age, sex, cognition
and disability.
Methods: We compared data from participants aged 65+ years from the Cognitive Function and Ageing Studies
(CFAS I and II), collected during 1990–1993 (N = 7635) and 2008–2011 (N = 7762). We estimated the prevalence of
potent anticholinergic use (Anticholinergic Cognitive Burden [ACB] score = 3) and average anticholinergic burden
(sum of ACB scores), using inverse probability weights standardised to the 2011 UK population. These were
stratified by age, sex, Mini-Mental State Examination score, and activities of daily living (ADL) or instrumental ADL
(IADL) disability.
Results: Prevalence of potent anticholinergic use increased from 5.7% (95% Confidence Interval [CI] 5.2–6.3%) of
the older population in 1990–93 to 9.9% (9.3–10.7%) in 2008–11, adjusted odds ratio of 1.90 (95% CI 1.67–2.16).
People with clinically significant cognitive impairment (MMSE [Mini Mental State Examination] 21 or less) were the
heaviest users of potent anticholinergics in CFAS II (16.5% [95% CI 12.0–22.3%]). Large increases in the prevalence of
the use medication with ‘any’ anticholinergic activity were seen in older people with clinically significant cognitive
impairment (53.3% in CFAS I to 71.5% in CFAS II).
Conclusions: Use of potent anticholinergic medications nearly doubled in England’s older population over 20 years
with some of the greatest increases amongst those particularly vulnerable to anticholinergic side-effects.
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Globally, the population is ageing; in the UK, the propor-
tion of people aged 65 years or over is projected to increase
from 18% in 2017 to 21% by 2027 [1]. Multi-morbidity
increases with ageing. This increase has been accompanied
by a dramatic rise in polypharmacy with the proportion of
older people taking five or more medication rising four-fold
from 12 to 49% over 20 years [2]. The concerns about
polypharmacy include interactions, burden on patients,
side effects, and cost. Many older people frequently
receive medicines with anticholinergic properties for di-
verse conditions, such as depression, bladder problems,
Parkinson’s disease and chronic obstructive pulmonary
disease [3–6].
Anticholinergic activity can cause cognitive decline, falls,
constipation and daytime drowsiness in older people [7,
8], and worsen cognition and activities of daily living in
people living with schizophrenia [9]. Greater cumulative
use of anticholinergics has been associated with an in-
creased risk of dementia [10–12], and mortality [7]. Given
these possible associations with long term outcomes as
well as the known immediate adverse anticholinergic
effects, it is widely accepted that these medicines should
be avoided in older people where possible [13]. Neverthe-
less, anticholinergics remain commonly prescribed.
Estimates of prevalence of anticholinergic use vary
depending on the population, year and definition of anti-
cholinergic medications. Previous estimates of the preva-
lence of any anticholinergic use in older adults have
varied from 37 to 63% [8, 14], and of ‘potent’ anticholin-
ergic use from 4 to 10% [8, 14, 15]. However, less is
known about the impact of anticholinergic effects among
groups most vulnerable to their side-effects such as
older people with clinically significant cognitive impair-
ment including those living with dementia and the very
old, because these groups are commonly excluded from
clinical trials [16, 17].
Medications with anticholinergic activity are most
commonly available only by prescription, but are also
obtainable over-the-counter. Hence pharmacy dispens-
ing or prescription databases may underestimate the true
prevalence of anticholinergic medication use in the
population. Prospective longitudinal studies, which aim
to ascertain participants’ over the counter (OTC) and
prescription medication use, may offer the best oppor-
tunities to understand changing patterns in their use.
These prospective longitudinal studies also allow the
disaggregation of older populations by health status and
so allow the medication use patterns to be described by
physical and cognitive frailty.
The overall aim of the study was to estimate the preva-
lence of anticholinergic use in England’s older popula-
tion in 1991 and 2011, and describe changes in use by
participant’s age, sex, cognition and disability.Methods
This study compared the prevalence of anticholinergic
medication use in the older population of England using
baseline data from two prospective longitudinal studies
conducting using identical methods in 1990/1993 and
2008/2011. The authors assert that all procedures con-
tributing to this work comply with the ethical standards
of the relevant national and institutional committees on
human experimentation and with the Helsinki Declaration
of 1975, as revised in 2008. All procedures involving
human subjects were approved by local and multi-centre
ethical committees (CFAS I: REC99/5/22, 05/MRE05/37;
CFAS II: 07/MRE05/48).
Data were obtained from the first waves of the Cogni-
tive Function and Ageing Studies: CFAS I and CFAS II.
The CFAS studies are population-based longitudinal
studies of ageing, where participants aged 65 and older
were randomly selected from the Family Health Service
Authority lists from specific areas of England and Wales,
and include community-based participants and those in
long-term care.
Potential participants were initially contacted via a letter
from their general practice. If the potential participant
provided written informed consent, this was followed by a
visit from a trained interviewer (often from a health-
related background) from a team of interviewers. The
interview was conducted in the participants’ place of resi-
dence using a structured, computer assisted interview with
direct data entry.
For potential participants considered to lack mental
capacity, as per the Mental Capacity Act in the UK, a re-
quest to a key informant, usually a close family member,
was made for an interview. The interviews were then
performed with the assistance of a proxy (often a close
family member).
Participants were interviewed between December 1990
and July 1993 (CFAS I), and between November 2008
and October 2011 (CFAS II).
Data from three centres from CFAS I of Cambridge-
shire (rural), Newcastle (urban) and Nottingham (urban)
were chosen to match the centres in CFAS II. Sampling
was stratified by age group (65–74 vs ≥75 years). CFAS I
and CFAS II had very similar designs and assessment
methods and so medication use prevalence estimates
can be directly compared [18]. The response rate was
80% in CFAS I and 56% in CFAS II [18]. Inverse prob-
ability weights are available for both studies to ensure
estimates reflect the age and sex structure of their re-
spective populations. CFAS I and II assessments include
questions about socio-demographic characteristics, resi-
dence (long-term care or community-dwelling), medica-
tions, health, activities of daily living (basic and
instrumental), and tests of cognitive function [18]. For
data access and study information visit www.cfas.ac.uk.
Table 1 Baseline participant characteristics in CFAS I and CFAS
II
Demographic characteristics CFAS I (N = 7,635) CFAS II (N = 7,762)
Sex
Male 3045 (39.9) 3534 (45.5)
Female 4590 (60.1) 4228 (54.5)
Age
64–69 1981 (25.9) 1939 (25.0)
70–74 1776 (23.3) 1873 (24.1)
75–79 1725 (22.6) 1624 (20.9)
80–84 1308 (17.1) 1278 (16.5)
85–89 615 (8.1) 737 (9.5)
90+ 230 (3.0) 311 (4.0)
Centre
Cambridgeshire 2601 (34.1) 2558 (33.0)
Newcastle 2522 (33.0) 2582 (33.3)
Nottingham 2512 (32.9) 2622 (33.8)
MMSE1
Median (IQR) 27 (24, 28) 28 (26, 29)
Disability
None 5236 (68.6) 4975 (64.1)
IADL disability 1048 (13.7) 1495 (19.3)
ADL-IADL disability 1267 (16.6) 981 (12.6)
Residence
Community-dwelling 7245 (94.9) 7565 (97.5)
Long term care 242 (3.2) 197 (2.5)
Cell entries denote n (%) unless otherwise specified
1139 and 255 participants had missing MMSE data in CFAS I and CFAS II
Abbreviations: CFAS Cognitive Function and Ageing Studies, CI confidence
interval, MMSE Mini-Mental State Examination, ADL activities of daily
living, IADL instrumental activities of daily living, SD standard deviation,
IQR Interquartile range
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Medication usage, both prescribed and over the counter,
was obtained by self-report. At interview, participants
were asked ‘Are you currently taking any medicines, tab-
lets or injections of any kind, either you buy yourself or
are prescribed by your doctor?’ Where possible packaging
was checked, with proxies supplying medication informa-
tion if required. All prescribed and over the counter medi-
cations were recorded using NHS Read codes [2]. Read
codes are a computerised comprehensive coded thesaurus
used within the NHS. Prescription and OTC medication
reported was scored 0 to 3 on the Anticholinergic Burden
Scale (ACB). Medication with in-vitro activity, but no clin-
ically relevant effect are scored 1. Medication with clinic-
ally relevant effects are scored 2 or 3 if associated with
delirium. Other medications are scored 0. For the full list
visit:
https://www.uea.ac.uk/documents/3306616/10940915/
Anticholinergics/088bb9e6-3ee2-4b75-b8ce-b2d59dc538c2
Details of the scale development are reported elsewhere
[4, 5]. For medications available in the UK, but not rated on
the ACB scale, we applied the same approach used and
thus scored (i) all thiazide diuretics, loop diuretics and anti-
histamines as 1, (ii) all tricyclic antidepressants as 3, and
(iii) all creams, eye and ear drops as 0. CFAS did not record
how medications were obtained, and some common medi-
cations with potential anticholinergic properties such as
chlorphenamine, ranitidine, cimetidine, and codeine prod-
ucts could be prescribed or purchased OTC. We defined
any anticholinergic use as the use of any medications scor-
ing 1, 2 or 3 on the ACB scale, potent anticholinergic use
as any scoring 3 on the ACB scale, and the anticholinergic
burden as the sum of ACB scores for all medications taken.
Population subgroups
We estimated anticholinergic use in groups defined by
sex, age (grouped in 5-year age bands), cognitive func-
tion (Mini-Mental State Examination [MMSE] ≤21,
MMSE 22–25, and MMSE 26–30 points) [19], and dis-
ability [measured by impairments in modified Townsend
activities of daily living (ADL) and instrumental activities
of daily living (IADL)] [20].
Statistical analysis
We estimated the prevalence of any anticholinergic
medication use, potent anticholinergic use and the aver-
age anticholinergic burden, using inverse probability
weights that accounted for non-response [18]. To com-
pare cohorts, estimates were standardised to the 2011
UK age and sex distribution, using 5-year age bands, to
account for changes in population structure. Prevalences
were also estimated in the pre-defined population sub-
groups. Participants with missing disability or MMSE
data were excluded from those comparisons.We used logistic regression to estimate odds ratios
(OR) for ‘potent’ and ‘any’ anticholinergic use in CFAS
II compared to CFAS I. We used negative binomial
regression to estimate the rate ratio comparing the anti-
cholinergic burden between the two cohorts, as anti-
cholinergic burden was an over-dispersed discrete
variable. The differences between cohorts were adjusted
for age, sex and centre and weighted for non-response.
We also tested for interaction effects between subgroups
and CFAS cohort to identify different trends over time
among the different groups of the older population.
Finally, the prevalence of the potent anticholinergic
medication by urological, antispasmodic, antipsychotic,
antidepressant, anxiolytic, parkinsonian and antihista-
mine classes was estimated in CFAS I and II.
Results
Population characteristics
CFAS I and II included data from 7635 and 7762 partici-
pants, respectively. Table 1 summarises the characteristics
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Standard Deviation (SD) age were similar, 75.3 (7.1) for
CFAS I vs 75.7 (7.3) for CFAS II, there was a greater pro-
portion aged over 85 years in CFAS II. Participants of
CFAS II were also slightly more likely to be men and have
more IADL disability than in CFAS I.
Potent anticholinergic use
The overall prevalence of potent anticholinergic use
among the over 65s increased from 5.7% (95% CI 5.2–
6.3%) to 9.9% (95% CI 9.3–10.7%) between CFAS I and II.
After adjusting for demographic differences, the odds ratio
for this increase was 1.90 (95% CI 1.67–2.16) (Table 2).
In CFAS II, 12.8% of women used a potent anticholin-
ergic compared to 7.0% of men. This is approaching
twice the rate in CFAS I for both sexes. Potent anti-
cholinergic use was not strongly related to age; but the
heaviest users in CFAS II were those with clinically sig-
nificant cognitive impairment (16.5% [95% CI 12.0–
22.3%] of those with an MMSE of 21 or less) and more
disability, with 20.8% (95% CI 17.6–24.5%) of the most
disabled using a potent anticholinergic compared toTable 2 Prevalence of any and potent anticholinergic use in CFAS I
Any anticholinergic use
Population Prevalence % (95% CI) Adjusted OR for
CFAS II vs CFAS Ia
CFAS I CFAS II OR (95% CI)
Overall 49.6 (48.4, 50.7) 64.3 (63.2, 65.4) 1.25 (1.17, 1.34)
By sex
Male 46.7 (44.9, 48.6) 61.3 (59.6, 62.9) 1.00
Female 51.3 (49.8, 52.8) 66.7 (65.2, 68.2) 1.14 (0.99, 1.30)
By age, years
64–69 44.4 (42.2,46.6) 53.5 (51.2,55.7) 1.00
70–74 48.2 (45.9,50.6) 62.9 (60.7,65.1) 1.33 (1.11, 1.60)
75–79 52.8 (50.4,55.2) 68.8 (66.4,71.0) 1.41 (1.17, 1.71)
80–84 54.3 (51.5,57.0) 73.0 (70.4,75.5) 1.48 (1.20, 1.82)
85–89 53.8 (49.6,58.0) 72.1 (68.5,75.5) 1.58 (1.21, 2.07)
90+ 50.7 (43.5,57.8) 75.5 (68.9,81.1) 2.10 (1.36, 3.22)
By cognition
MMSE ≤21 53.3 (49.0, 57.6) 71.5 (65.0, 77.1) 1.00
MMSE 22–25 52.7 (50.2, 55.1) 69.9 (67.1, 72.6) 0.94 (0.70, 1.25)
MMSE 26–30 48.6 (47.0, 50.2) 62.8 (61.5, 64.1) 0.76 (0.59, 0.99)
By disability
No impairment 42.4 (40.8,44.0) 56.9 (55.4,58.5) 1.00
IADL impairment 67.1 (64.0,70.0) 80.4 (78.1,82.5) 1.13 (0.93, 1.36)
ADL impairment 71.1 (67.7,74.3) 85.4 (82.3,88.1) 1.15 (0.92, 1.43)
Weighted for nonresponse and standardised by the UK 2011 age population, missin
Abbreviations: CFAS Cognitive Function and Ageing Studies, CI confidence interval, M
instrumental activities of daily living
aAdjusted for age, sex and centre
bGlobal test for the interaction between the covariate and difference in prevalence6.3% (95% CI 5.6–7.1%) of those with no disability. The
greatest rate of increase between cohorts was seen
among those with IADL disability (from 6.8% [95% CI
5.4–8.7%] in CFAS I to 15.8% [95% CI 13.8–18.0%] in
CFAS II, p-value for interaction = 0.05).
The increases in potent anticholinergic use were
driven by an increased use of anticholinergic urologicals
and antidepressants (Table 3). Use of potent anticholin-
ergic urologicals and antidepressants increased from
0.3% (95% CI 0.2–0.4%) to 2.8% (95% CI 2.4–3.2%) and
4.0% (95% CI 3.6–4.5%) to 5.9% (95% CI 5.4–6.5%) be-
tween CFAS I and CFAS II, respectively. The most com-
mon anticholinergic urologicals used in CFAS II were
oxybutynin (35% of anticholinergic urological drugs),
tolterodine (31%) and solifenacin (17%), and the most
common anticholinergic antidepressant reported in
CFAS II was amitriptyline (69% of anticholinergic anti-
depressant drugs).
Any anticholinergic use
The prevalence of medication use with ‘any’ anticholin-
ergic activity increased from 49.6% (95% CI 48.4–50.7%)and CFAS II, by age, sex, cognition and disability
Potent anticholinergic use
Prevalence % (95% CI) Adjusted OR for
CFAS II vs CFAS Ia
pb CFAS I CFAS II OR (95% CI) pb
< 0.001 5.7 (5.2, 6.3) 9.9 (9.3, 10.7) 1.90 (1.67, 2.16) < 0.001
0.06 3.6 (3.0, 4.4) 6.4 (5.6,7.3) 1.00 0.59
7.0 (6.3, 7.8) 12.8 (11.7,13.9) 1.08 (0.82, 1.43)
< 0.001 5.2 (4.3,6.3) 8.0 (6.8,9.5) 1.00 0.49
5.9 (4.9,7.1) 9.9 (8.6,11.4) 1.11 (0.76, 1.60)
6.0 (4.9,7.2) 11.3 (9.7,13.0) 1.28 (0.88, 1.86)
6.8 (5.5,8.3) 11.0 (9.3,12.9) 1.09 (0.73, 1.62)
5.3 (3.7,7.5) 11.8 (9.5,14.6) 1.59 (0.95, 2.69)
4.1 (2.0,8.0) 9.0 (5.9,13.6) 1.54 (0.63, 3.75)
0.02 11.2 (8.6,14.4) 16.5 (12.0, 22.3) 1.00 0.83
6.7 (5.6,8.1) 13.4 (11.4,15.6) 1.10 (0.71, 1.70)
4.5 (3.9,5.2) 8.4 (7.7,9.2) 1.00 (0.68, 1.49)
0.27 3.8 (3.3, 4.5) 6.3 (5.6, 7.1) 1.00 0.05
6.8 (5.4, 8.7) 15.8 (13.8, 18.0) 1.46 (1.04, 2.04)
15.8 (13.1,18.9) 20.8 (17.6, 24.5) 0.95 (0.70, 1.29)
g cases excluded
MSE Mini-Mental State Examination, ADL activities of daily living, IADL
between CFAS I and CFAS II
Table 3 Prevalence of potent anticholinergic use in CFAS I and
CFAS II, by drug class
Potent anticholinergic class 1991 CFAS I 2011 CFAS II
Urological 0.3 (0.2, 0.4) 2.8 (2.4, 3.2)
Antispasmodic 0.5 (0.3, 0.6) 0.3 (0.2, 0.5)
Antipsychotic 1.0 (0.8, 1.2) 0.9 (0.7, 1.1)
Antidepressant 4.0 (3.6, 4.5) 5.9 (5.4, 6.5)
Anxiolytic N/A 0.2 (0.1, 0.3)
Parkinsonian 0.2 (0.2, 0.4) 0.1 (0.0, 0.2)
Antihistamine 0.2 (0.1, 0.3) 0.5 (0.3, 0.7)
Cell entries denote % prevalence (95% confidence intervals)
Abbreviations: CFAS Cognitive Function and Ageing Studies
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CFAS II (Table 2, adjusted OR of 1.25; 95% CI 1.17–
1.34). The greatest increases in use across the 20 years
was observed for older participants (from 50.7% [95% CI
43.5–57.8%] in CFAS I to 75.5% [95% CI 68.9–81.1%] in
CFAS II for those aged 90 years or more, p-value for
interaction < 0.001), and in those with clinically signifi-
cant cognitive impairment (from 53.3% [95% CI 49.0–
57.6%] in CFAS I to 71.5% [95% CI 65.0–77.1%] in CFASTable 4 Average anticholinergic burden in CFAS I and CFAS II, by a
Population Mean ACB sum (95% CI)
CFAS I CFAS II
Overall 0.99 (0.96, 1.03) 1.11 (1.08, 1
By sex
Male 0.91 (0.86, 0.95) 0.96 (0.92–1
Female 1.05 (1.01, 1.09) 1.23 (1.18–1
By age, years
64–69 0.87 (0.81, 0.92) 0.81 (0.75–0
70–74 0.97 (0.91, 1.04) 1.10 (1.03–1
75–79 1.09 (1.02, 1.15) 1.26 (1.18–1
80–84 1.12 (1.04, 1.20) 1.28 (1.19–1
85–89 1.07 (0.95, 1.18) 1.37 (1.25–1
90+ 0.97 (0.77, 1.17) 1.36 (1.17–1
By cognition
MMSE ≤21 1.29 (1.13, 1.46) 1.32 (1.13, 1
MMSE 22–25 1.09 (1.02, 1.16) 1.38 (1.28, 1
MMSE 26–30 0.93 (0.89, 0.97) 1.04 (1.01, 1
By disability
No impairment 0.76 (0.72, 0.79) 0.85 (0.81, 0
IADL impairment 1.51 (1.40, 1.61) 1.64 (1.54, 1
ADL impairment 1.85 (1.71, 1.99) 1.88 (1.74, 2
Prevalence (95% confidence interval) displayed, weighted for nonresponse and stan
Abbreviations: ACB Anticholinergic Cognitive Burden scale, CFAS Cognitive Function
daily living, IADL instrumental activities of daily living
aAdjusted for age, sex and centre
bGlobal test for the interaction between the covariate and ratio of total anticholinerII for those with an MMSE score of 21 or lower, p-value
for interaction = 0.02).
Anticholinergic burden
The average total anticholinergic burden increased from
0.99 (95% CI 0.96–1.03) in 1991 to 1.11 (95% CI 1.08–
1.15) in 2011, adjusted ratio of 1.12 (95% CI 1.07–1.17)
(Table 4).
Women and older participants had the greatest total
burden score, and had experienced the greatest increases
since CFAS I. For example the mean ACB score in-
creased from 1.05 (95% CI 1.01–1.09) in CFAS I to 1.23
(95% CI 1.18–1.28) in CFAS II for women (p-value for
interaction = 0.01), and from 0.97 (95% CI 0.77–1.17) in
CFAS I to 1.36 (95% CI 1.17–1.54) in CFAS II for those
aged 90 years or more (p-value for interaction< 0.001).
Discussion
The prevalence of potent anticholinergic use in the older
population in England nearly doubled between 1990/93
and 2008/11. After adjustment for demographic variables,
we found that participants in the later study (CFAS II)
were 1.9 times more likely to be on potent anticholinergics
as compared to participants in the earlier study (CFAS I).ge, sex, cognition and disability
Adjusted rate ratio for CFAS II vs CFAS Ia
Rate ratio (95% CI) pb
.15) 1.12 (1.07, 1.17) < 0.001
.01) 1.00 0.01
.28) 1.12 (1.03, 1.23)
.87) 1.00 < 0.001
.66) 1.21 (1.05, 1.38)
.34) 1.24 (1.09, 1.42)
.36) 1.22 (1.06, 1.41)
.49) 1.39 (1.17, 1.66)
.54) 1.53 (1.17, 1.99)
.52) 1.00 0.03
.48) 1.11 (0.94, 1.31)
.09) 0.97 (0.83, 1.13)
.89) 1.00 0.91
.74) 1.02 (0.92, 1.13)
.03) 1.02 (0.91, 1.14)
dardised by the UK 2011 age population, with missing cases excluded
and Ageing Studies, MMSE Mini-Mental State Examination, ADL activities of
gic burden between CFAS I and CFAS II
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use of anticholinergic urologicals (common drugs were
oxybutynin, solifenacin and tolterodine) and antidepres-
sants (the most common being amitriptyline). More than
one in five of those with an impairment in activities of
daily living, and one in six of those with MMSE less than
21, indicating clinically significant cognitive impairment
including dementia, reported use of a potent anticholiner-
gic medication in CFAS II, both significantly higher than
in CFAS I [21]. This is despite guidance suggesting
cautious use of these drugs. Those with IADL disability
had the greatest disproportionate increases in potent anti-
cholinergic use. Women and older participants also had
disproportionately greater increases in total anticholiner-
gic burden between study periods.
A number of studies have described changes in the rates
of anticholinergic prescribing [16, 17]. A study in Scotland
examined changes in the numbers of prescriptions of anti-
cholinergic medications, from 1995 to 2010, and found a
statistically significant but modest increase in the number
of older people prescribed any anticholinergic (20.7% vs
23.7%, p < 0.001) [16]. A repeated cross-sectional analysis
of office-based outpatient visits for older people in the
USA found that the prevalence of high-risk anticholinergic
prescriptions was stable from 2006 to 2015; it increased
from 6.1% in 2006–07 to 6.8% in 2008–09 and decreased
to 4.7% by 2014–15 [17]. However, previous studies have
not been able to include over-the-counter medication use
nor describe use in vulnerable patient groups; the US
study also only included prescriptions issued by the phys-
ician at the sampled visit.
We observed an increase in anticholinergic urological use
between 1991 and 2011, partly because many of the com-
monly used urologicals were only introduced in the 1990s,
or later. Other studies have also reported increases in the
prescribing of anticholinergic urologicals [16, 22, 23]. A
23% increased number of new users of anticholinergics for
overactive bladder was reported in a UK study (from 12,
598 in 2004 to 15,441 in 2012) [23]. A significant increase
in the proportion of women presenting to physicians with
urinary incontinence then prescribed bladder anticholiner-
gics was also reported in the US (16.7% in 1999 to 35.0% in
2009, p = 0.006) [22].
Use of anticholinergic antidepressants also increased be-
tween CFAS I and II; confirming other studies [24]. In
addition to anticholinergic effects, antidepressants are as-
sociated with hyponatraemia [25, 26]. Even mild hypona-
traemia induced by antidepressants may worsen cognition
and cause falls compounding apparent anticholinergic ef-
fects [25]. Depression is also an early sign of dementia and
therefore older people with depression may be particularly
vulnerable to cognitive anticholinergic effects [27].
Anticholinergics can have a significant impact on
morbidity in older people particularly those living withany form of clinically significant cognitive impairment
including dementia [7, 12]. Anticholinergics can worsen
dementia, cause numerous anticholinergic effects, both
centrally and peripherally, and may be associated with
an excess mortality [7, 12]. Equally importantly, anticho-
linergics could also worsen the quality of life of the older
person and any informal (family) carer [28].
The large increase in the use of potent anticholinergics
among people with clinically significant cognitive impair-
ment and physical disabilities is particularly concerning.
There is increasing evidence, from recent research, that
such usage is associated with an increased risk of dementia
[10, 11, 12]. Furthermore, anticholinergic cognitive effects
are likely to have more severe consequences, such as medi-
cation errors, in people with less cognitive reserve for ex-
ample dementia or traumatic brain injury [29]. Medication
management itself is an instrumental activity of daily living
with high demands on memory and executive function
[30], and so anticholinergic induced cognitive impairment
may increase the risk of both non-adherence to medica-
tion, and medication errors [30, 29]. This in turn will in-
crease dependency on informal carers worsening the
burden on informal carers [31].
Strengths and weaknesses
Frail older people with multi-morbidities including those
with dementia are frequently excluded from controlled
trials, and so effectiveness of anticholinergics is rarely
directly assessed, and observational studies are vital for
monitoring risks. Strengths of this study include the
population-based sampling in CFAS from the same geo-
graphic areas 20-years apart and to ascertain key patient
characteristics, cognition and disability associated with
medication use. Although most anticholinergics are pre-
scribed, a further strength of our study was the ability to
more accurately capture the full range of anticholinergic
use, by including OTC medications.
This appropriateness of prescribing was not assessed
as part of the CFAS study. The increase in use of anti-
cholinergics might reflect improvements in diagnosis
and better access to treatment for conditions such as in-
continence, depression and pain. Such conditions can be
very debilitating, and for clinicians and patients the key
issue is balancing the risks versus the benefits.
Our study has some limitations. The accuracy of the
self-reported medication use and the duration of treat-
ment is unknown. Although, to increase the accuracy of
the reporting, interviewers requested, where possible, to
see the medication packages (and repeat prescription
scripts) to enter correct drug names, we cannot be sure if
the participants were adherent to the medication. The
data used is from 1990 to 1993 and 2008 to 2011 and
therefore we recommend that the study is repeated with
more recent data to examine whether the trends continue.
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tion use post 2011 are rare. Increased prescribing of anti-
cholinergics for overactive bladder has been reported until
2012 for adults [23]. Warnings against antipsychotic use
in dementia has decreased prescribing to these patients
[32], but we lack information on the general older popula-
tion. Antidepressant prescribing has been increasing from
2013 to 18, but detail has not been provided by anticholin-
ergic antidepressants or for older people specifically [33].
We used the ACB scale to identify anticholinergic medi-
cations, however this is one of 18 different scales that all
vary in their content and how they are derived and how
anticholinergic activity is quantified [34]. However, the
scales closely agree on which medications they classify as
potently anticholinergic. The response rate was lower in
CFAS II, and it is not clear whether this would under-
estimate or over-estimate medication use in this cohort.
We used inverse probability weights to correct age and
sex distributions for non-response, and conducted ana-
lyses stratified by levels of cognitive function and disabil-
ity, and so our findings are unlikely to be biased by
differential non-response between cohorts [18]. Our study
is descriptive and we did not have sufficient comorbidity
data to sufficiently examine why older people in the
various subgroups had increased anticholinergic use, but
increased diagnoses of conditions for which anticholiner-
gics are indicated for is likely a factor.Future research
Further research is needed to monitor anticholinergic
use within vulnerable populations, particularly older
people living with clinically significant cognitive impair-
ment including dementia, in the UK since 2011 and in
other countries. We also need a clearer understanding of
the relative risk versus benefit of anticholinergics and in
whom the risk is greatest, and the effectiveness of inter-
ventions to reduce the harm associated with anticholin-
ergics. Interventions to limit the use of inappropriate
anticholinergics require development and testing; a real-
ist approach, which focuses on the key importance of
context and mechanism offers a promising avenue for
such intervention development [35–37].Conclusions
In summary the use of potent anticholinergics nearly
doubled in the older population in England over an
appropriate 20 year period (from 1990/93 to 2008/11),
largely due to rising use of antidepressants and urologi-
cals. The use of anticholinergics is highest among the
most vulnerable groups including people living with
clinically significant cognitive impairment. This raises
concerns as anticholinergic medications are associated
with a range of side-effects including cognitive decline.Abbreviations
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